Overview

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fox Chase Cancer Center
Collaborators:
Genentech, Inc.
OSI Pharmaceuticals
Treatments:
Bevacizumab
Erlotinib Hydrochloride